Mega Millions set for first drawing with new $5 ticket
The Mega Millions lottery will have its first drawing Tuesday night since game officials rolled out a new $5 price tag for each ticket.
The game group first announced the new ticket price in October as part of a series of tweaks that it said will improve the odds of a jackpot — although the odds remain extremely long.
The new odds of a jackpot win are 1 in 290,472,336, compared with 1 in 302,575,350, the group said in news release about the changes on March 25.
The improved odds for a jackpot and a win of any prize are because of the removal of one gold Mega Ball from the mix — from 25 Mega Balls to 24 — the game group said.
Before the price increase, tickets had cost $2 each.
'Beyond big jackpots, players told us they want bigger non-jackpot prizes and that's exactly what this new game delivers,' Joshua Johnston, lead director of the Mega Millions Consortium, said in a statement last month.
There have been changes to the Mega Millions before, most recently in response to the Covid-19 pandemic.
In October 2017, the game doubled the price of tickets from $1 to $2 and increased starting jackpots from $15 million to $40 million, which was designed to swell jackpots.
Then in 2020, because of slowing sales during the pandemic, the game was changed again, dropping the starting jackpot from $40 million to $20 million and eliminating a minimum jackpot increase. The increase instead was tied to ticket sales, which is how it still grows.
The new game scheme raises the starting jackpot to $50 million.
Tuesday's drawing, the first with the new $5 tickets, is scheduled for 11 p.m. ET. The estimated jackpot is $54 million.
CORRECTION: (April 8, 9:15 p.m. ET) A previous version of this article misstated when the new ticket price was announced. It was in October, not March.
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
23 minutes ago
- Boston Globe
FDA looks to AI to enhance efficiency
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The agency plays a central role in pursuing the agenda of the US health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly. Advertisement Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that AI is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device. Advertisement 'I don't want to be dismissive of speeding reviews at the FDA,' said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. 'I think that there is great potential here, but I'm not seeing the beef yet.' A major AI rollout closely follows the release of a report by Kennedy's MAHA Commission, which uses an acronym for Make America Healthy Again, that was found to be rife with references to scientific research apparently fabricated by an AI program. For some cases, the FDA officials proposed speeding major drug approvals by requiring only one major study in patients rather than two, a practice the agency has used in recent years. The pandemic provided a precedent, they said, for accelerating the process. 'We believe this is clear demonstration that rapid or instant reviews are possible,' Makary and Prasad wrote. But Holland pointed out that during the pandemic, many staff members were transferred from routine duties, including overseas inspections of food or drug facilities, and reassigned to hasten critical COVID product reviews. The agency was also better staffed. In recent months, the FDA shed about 1,940 employees, reducing the workforce to 8,000 from roughly 10,000. Last week, the agency introduced Elsa, an AI large-language model similar to ChatGPT. The FDA said it could be used to prioritize which food or drug facilities to inspect, to describe side effects in drug safety summaries and to perform other basic product-review tasks. The FDA officials wrote that AI held the promise to 'radically increase efficiency' in examining as many as 500,000 pages submitted for approval decisions. Advertisement Current and former health officials said the AI tool was helpful but far from transformative. For one, the model limits the number of characters that can be reviewed, meaning it is unable to do some rote data analysis tasks. Its results must be checked carefully, so far saving little time. Staff members said the model was hallucinating, or producing false information. Employees can ask the Elsa model to summarize text or act as an expert in a particular field of medicine. Makary said the AI models were not being trained by data submitted by the drug or medical device industry. When it comes to food oversight, Makary and Prasad said there would be a renewed focus on 'our increasingly chemically manipulated diet,' a goal embraced by Republicans and Democrats. 'For all additives,' the article said, 'the benefit-to-harm balance must be reevaluated.' Although the Trump administration is seeking steep cuts in the FDA's budget for the next fiscal year, the food division is expected to receive additional funds. Others noted the fine line agency officials were walking, given Kennedy's complaints that the FDA is too close to the drug industry and the Trump administration's business-friendly approach. Makary and Prasad wrote that the FDA must be 'partners with industry' while avoiding 'a cozy relationship that has characterized the agency in the past.' Dr. Reshma Ramachandran, a director of the Yale Collaboration for Regulatory Rigor, Integrity and Transparency, pointed out that Makary and Prasad were going on a six-city, closed-door listening tour to meet with chief executives of the drug industry. 'How is this guarding the agency 'against a cozy relationship' with industry?' she asked. The FDA priorities 'read as though they're straight out of PhRMA's playbook,' she said, referring to the trade group. Advertisement This article originally appeared in
USA Today
30 minutes ago
- USA Today
Brace yourself for more ads before movies at AMC theaters, reports say
Brace yourself for more ads before movies at AMC theaters, reports say Show Caption Hide Caption AMC, Regal investing $2.2B to upgrade movie theater experience The eight biggest movie theater chains in the U.S. and Canada — including AMC and Regal — will invest $2.2 billion to make upgrades. Straight Arrow News Moviegoers, brace yourselves. The dreaded advertisements before a movie are expected to get longer at AMC Cinemas, according to multiple reports. The cinema chain is joining major competitors in running even more commercials starting in July under a new partnership with cinema advertising company National CineMedia (NCM), multiple outlets including Bloomberg and the New York Times reported. The move comes in an effort to increase revenue without raising ticket prices as cinemas continues to struggle financially and recover from the COVID-19 losses, The Hollywood Reporter reported. Under the deal, AMC will play commercials in what is known as the 'platinum spot,' the part right before the movie begins, in complete contrast to its 2019 decision in which it had shunned NCM's proposal to place ads in that spot. National CineMedia had gone on to sign agreements with two of AMC's rivals, Regal and Cinemark, that year, according to NYT. "AMC has no plan to introduce commercial advertising close to the start of a movie's commencement at its theatres in the United States, nor does AMC envision entering into such an arrangement with NCM anytime in the foreseeable future," the cinema chain had said in a September 2019 statement. AMC further said the concept "of commencing a platinum advertising position during the end of trailer play," was "flatly rejected" "because of AMC's concerns that U.S. moviegoers would react quite negatively to the concept." AMC prepared for backlash While AMC did not immediately respond to USA TODAY's request for a comment on the latest development, the chain in a statement to NYT suggested it was prepared for criticism and backlash, noting the decision would not impact the customer's wallets. 'For the past five years, AMC has sought out crucial revenue that is not reliant on the increase of base ticket prices,' the company said in the statement to NYT, adding 'while AMC was initially reluctant to bring this to our theaters, our competitors have fully participated for more than five years without any direct impact to their attendance.' Both AMC and NCM are expected to share revenues from the new pre-movie advertising window, according to The Hollywood Reporter. National CineMedia also did not respond to USA TODAY's request for comment. It is not known how long the pre-show and advertisements would run and what kind of ads viewers can expect to see. Saman Shafiq is a trending news reporter for USA TODAY. Reach her at sshafiq@ and follow her on X and Instagram @saman_shafiq7.
New York Post
an hour ago
- New York Post
UES pol pushes crackdown on NYC ‘broken' emergency contracting system
An Upper East Side councilwoman wants to crack down on the mayor's ability to dole out controversial no-bid contracts after a series of high-profile boondoggles during the migrant and COVID crises. Councilmember Julie Menin is proposing two new bills in the aim to curb financial fiascos tied to such contracts — like the controversial $432 million sweetheart deal with DocGo that had taxpayers footing the bill for uneaten meals and empty migrant shelters. 'It's time for drastic change by reforming the city's excessive emergency procurement practices that lack vital checks and balances,' Menin said. The measures would cap the mayor's emergency contracting powers at 30 days and force quicker audits of the deals. 3 Julie Menin wants to fix the city's 'broken' emergency contract procurement process. Leonardo Munoz Current law allows the mayor to dole out non-competitive contracts lasting up to one year during a declared emergency. Menin said the frantic procurement process squanders billions in taxpayer dollars due to waste and malfeasance. She pointed to the COVID-19 pandemic, when then-Mayor Bill de Blasio extended emergency declarations over 100 times, spending an eye-popping $7 billion on emergency supplies with little oversight. It led to New York City loading up on mountains of the supplies, which became unnecessary when the crisis ended. 3 The de Blasio administration spent billions on non-competitive emergency contracts during the COVID pandemic. RICHARD HARBUS Under one COVID-era contract, the city spent as much as $7.50 per cloth mask, Menin said. When city officials auctioned off $225 million leftover PPE supplies, they only recouped $500,000. 'These are reforms to a broken contracting system which has price gouged our government,' Menin said. Mayor Eric Adams has also faced intense scrutiny over the emergency contracts handed out during the emergency he declared over the influx of migrants arriving to the city. The Adams administration awarded DocGo contracts worth hundreds of millions of dollars — without a bidding process to hear from other firms — to operate migrant shelters, despite the company having little experience on the matter. 3 The Adams administration doled out more than $5 billion in emergency contract during the migrant crisis. Michael Nigro Reports showed the contractor used unlicensed security guards, tossed thousands of uneaten meals and underutilized shelter space — eventually leading to an investigation by the state Attorney General's Office and the termination of the deal. 'The failures surrounding DocGo for a critical service only reinforced the need for reforming our broken emergency procurement process,' Menin said. One of Menin's bills would also mandate public disclosure of subcontractors, with penalties of up to $100,000 for failing to report financial relationships. 'Recent mayoral administrations have shown no appetite for good government contracting practices and it's time for the City Council to advance vital legislation to save taxpayer dollars, be fiscally responsible and root out corruption,' she said.
